Figure 3.
Solving the puzzle of alloHCT for older patients with hematologic malignancies. MRD, measurable residual disease; PPx, prophylaxis.
Solving the puzzle of alloHCT for older patients with hematologic malignancies. MRD, measurable residual disease; PPx, prophylaxis.